A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Trial Details

NCT ID
NCT07022483
Phase
PHASE3
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Trastuzumab Deruxtecan
  • Chemotherapy
Locations (sample)
  • Fort Lauderdale, Florida, United States|26.12231,-80.14338
  • Miami, Florida, United States|25.77427,-80.19366
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • Orlando, Florida, United States|28.53834,-81.37924
  • Fort Wayne, Indiana, United States|41.1306,-85.12886

Key Eligibility Criteria

  • Adults ≥18 years at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is …
  • Has histologically confirmed diagnosis of epithelial endometrial carcinoma. All histology's are allowed except for sarcomas (carcinosarcomas are al…
  • Is newly diagnosed FIGO 2023 Stage IIC (including Stage IICmp53abn) or Stage III Note: FIGO 2023 Stage IIC includes disease with aggressive histolo…
  • Has HER2-expression (IHC 3+/2+).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →